Key Stats for Regeneron Stock
- Price change for Regeneron stock: -6%
- $REGN Share Price as of Apr. 29: $686
- 52-Week High: $821
- $REGN Stock Price Target: $878
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Regeneron (REGN) stock is down over 9% in the last five trading sessions despite the company reporting a solid Q1. On paper, the results look good.
- Total revenues grew 19% year-over-year to $3.61 billion.
- Non-GAAP earnings per share rose 15% to $9.47.
- Dupixent, the company’s flagship drug, posted $4.9 billion in global net sales, up 31% on a constant currency basis.
So why is Regeneron stock down?
- A few things spooked investors. The biggest issue is EYLEA. Combined U.S. sales for EYLEA and EYLEA HD came in at $942 million, but regular EYLEA US sales fell 36% year-over-year as patients switched to the newer EYLEA HD version.
- On top of that, the FDA missed its April deadline to rule on the EYLEA HD pre-filled syringe application. That decision is still pending, and the uncertainty around it clearly rattled the market.
- There was also a setback in oncology. An experimental drug combination targeting lung cancer will not move forward to late-stage trials.
That’s a pipeline disappointment, even if management downplayed it on the earnings call.
Despite all the good news, including FDA approval of a new gene therapy called Otarmeni for genetic hearing loss (which Regeneron is offering for free), and a new $3 billion share repurchase program, none of it was enough to offset these concerns.
See analysts’ growth forecasts and price targets for Regeneron stock (It’s free) >>>
What the Market Is Telling Us About Regeneron Stock
Regeneron stock often gets punished when EYLEA disappoints. The drug has been a major revenue driver for years, and investors are closely watching the transition to EYLEA HD. Any regulatory delay or slower-than-expected adoption raises questions.
The share buyback is a positive signal. Management clearly believes the stock is undervalued. But right now, the market is focused on the risks, not the reassurances.
Regeneron stock has a strong long-term story, especially with Dupixent continuing to grow and a deep pipeline across oncology, rare diseases, and obesity. But today, the negatives are winning.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Regeneron Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
